In a crisp January evening, the free community library at Masoodpur in South Extension transformed into a portal of another ...

Alterity Therapeutics (ATHE) issued a letter to shareholders from CEO David Stamler, stating in part: “As we again begin a new year, I am filled with optimism for 2025 and what lies ahead for Alterity ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments ...

澳大利亚墨尔本和美国新泽西州普林斯顿 - 专注于开发视网膜疾病治疗方法的生物制药公司Opthea Limited (ASX/NASDAQ: OPT)在同行评审期刊《转化视觉科学与技术》上发表了其sozinibercept治疗糖尿病黄斑水肿 (DME)的1b期试验结果。该研究评估了sozinibercept与标准抗VEGF-A疗法aflibercept联合使用在持续性DME患者中的安全性和有效性。

Other stars in December included Orthocell (ASX:OCC), which was up 67% amid “outstanding” clinical trial results and expected ...

Alterity Therapeutics Ltd. ( ) has provided an update. Alterity Therapeutics announced a change in the director’s interest as Mr. Brian Meltzer acquired 30,000,000 unlisted opti ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Alterity Therapeutics Ltd. (AU:ATH) has released an update.Don't Miss Our New Year's Offers:Discover the latest stocks recommended by top Wall ...

all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Alterity Therapeutics Ltd. has announced the issuance of 170 ...